|
|
Constellation
Pharmaceuticals and Genentech Enter Broad Epigenetics Drug Discovery
Collaboration
January 17, 2012
PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust
December 22, 2011
Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
December 2, 2011
PTC Therapeutics and Roche sign agreement to advance treatment for Spinal Muscular Atrophy (SMA)
November 29, 2011
Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer
October 18, 2011
PTC Therapeutics
and Genzyme Announce Restructuring of Collaboration
September 2, 2011
3-V Biosciences
Appoints George W. Kemble, PhD, as Chief Scientific Officer
August 15, 2011
Peloton Therapeutics Completes $18 Million Series A Financing
July 27, 2011
PTC Publishes Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis in the European Respiratory Journal
July 1, 2011
PTC Therapeutics and AstraZeneca
Announce Strategic Oncology Drug Discovery Collaboration with Potential
Extension to Other Therapeutic Areas
June 29, 2011
Cyterix
Pharmaceuticals Raises $9.2 Million in a Series A Venture Financing
June 7, 2011
Constellation Pharmaceuticals Raises $15 Million in Additional Funding
June 6, 2011
Immune Design Corporation Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer
April 27, 2011
PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer
March 30, 2011
Constellation
Pharmaceuticals Expands Leadership Team with Drug Development Industry Veterans
February 1, 2011
Constellation Pharmaceuticals Appoints Industry Veteran James E. Audia, Ph.D. as Chief Scientific Officer
January 4, 2011
PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
December 21, 2010
PTC Therapeutics Publishes Results From Phase 2 Study of Ataluren in Children with Cystic Fibrosis
November 15, 2010
PTC Therapeutics Initiates Phase 2 Clinical Trial of Ataluren in Patients with Methylmalonic Acidemia
October 26, 2010
Immune Design Grants Adjuvant License to MedImmune
October 26, 2010
PTC Therapeutics pivotal data presented at the World Muscle Society Congress suggest Ataluren slows the loss of walking ability in patients with nonsense mutation Duchenne/Becker muscular dystrophy
October 15, 2010
NGM Biopharmaceuticals Names William J. Rieflin Chief Executive Officer and Director
October 4, 2010
3-V Biosciences Appoints Merdad V.
Parsey, MD, PhD, as Chief Executive Officer
September 30, 2010
Aragon Pharmaceuticals Doses First Patient in Phase 1/2 Clinical Trial of ARN-509 for Castration-Resistant Prostate Cancer
August 9, 2010
Aragon Pharmaceuticals Appoints Richard A. Heyman CEO
August 2, 2010
Igenica, Inc. secures $24 million in Series B financing
June 10, 2010
3-V Biosciences Appoints Edward M. Connor, Jr., MD, Chief Medical Officer
June 3, 2010
Constellation Pharmaceuticals Closes $22 Million in Series B Funding
June 2, 2010
3-V Biosciences Expands Leadership Team, Opens New Facility and Integrates Operations
May 13, 2010
Aragon Pharmaceuticals Secures $22 Million in Series B Financing
April 22, 2010
NGM Biopharmaceuticals Raises $51 Million in Series B Financing and Appoints New Board Member
March 15, 2010
PTC Therapeutics Closes $50 Million Financing
December 22, 2009
Constellation's CSO and Scientific Advisor Receive Medal of Honor from American Cancer Society
November 23, 2009
The Column Group
Announces Expansion of Investment Team - Names Magnus Persson Managing Partner
November 5, 2009
Aragon Pharmaceuticals' Founder, Dr. Charles Sawyers Awarded 2009 Lasker-DeBakey Clinical Medical Research Award
October 27, 2009
NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, former Genentech CEO, to its Board of Directors
October 21, 2009
Constellation Pharmaceuticals Appoints Renowned Cancer Biologist Edward E.
Harlow, Jr., Ph.D. as Company's CSO
September 9, 2009
NGM Biopharmaceuticals Appoints Helen S. Kim as Chief Business Officer
September 1, 2009
Constellation Pharmaceuticals Appoints Mark A. Goldsmith, M.D., Ph.D. as
CEO and Closes $17 Million in Funding
August 13, 2009
3-V Biosciences Secures $30 Million in Series B Funding, Welcomes New
Members to Board of Directors
July 10, 2009
Aragon Pharmaceuticals Announces $8 Million Series A Financing
May 20, 2009
Igenica Appoints Dr. Mike Rothe as CEO
After Closing Series A Financing
March 9th, 2009
IDRI and Immune Design Enter License Agreement on GLA Vaccine Adjuvant
November 20, 2008
FierceBiotech Names Constellation Pharmaceuticals as One of the "Fierce 15"
Biotech Companies of 2008
June 24, 2008
Immune Design, Led By Star Scientists, Raises $18 Million To Build Vaccine
Company
June 23, 2008
Constellation Pharmaceuticals Closes $32 Million in Series A Funding
April 29, 2008
NGM Biopharmaceuticals Raises $25.5M
February 12, 2008
|
